Pipeline

ENYO Pharma is advancing its pipeline with Vonafexor series for diseases with impaired kidney function as CKD, Alport syndrome, MASH and DKD.

Vonafexor (EYP001)

• Molecule: small molecule; synthetic and non-steroidal agonist of NR1H4 (farnesoid X receptor, FXR or bile acid receptor)
• Drug profile: distributed mainly to both the kidney and the liver
• Administration mode: oral (tablet), once a day
• Mode of Action: fibrolytic and anti-inflammatory
• Clinical development: supported by 9 completed clinical studies: 6 Phases 1 and 3 Phases 2a ; currently in Phase 2 for Alport syndrome and CKD in patients with MASH